Home › Compare › CAMRF vs NNN

CAMRF vs NNN: Dividend Comparison 2026

CAMRF yields 3.64% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNN wins by $247.00 in total portfolio value· pulled ahead in Year 10
10 years
CAMRF
CAMRF
● Live price
3.64%
Share price
$55.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.40
Full CAMRF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — CAMRF vs NNN

📍 NNN pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAMRFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAMRF + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CAMRF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAMRF
Annual income on $10K today (after 15% tax)
$309.09/yr
After 10yr DRIP, annual income (after tax)
$390.49/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $1,851.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAMRF + NNN for your $10,000?

CAMRF: 50%NNN: 50%
100% NNN50/50100% CAMRF
Portfolio after 10yr
$25.4K
Annual income
$1,548.41/yr
Blended yield
6.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

CAMRF
No analyst data
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAMRF buys
0
NNN buys
0
No recent congressional trades found for CAMRF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAMRFNNN
Forward yield3.64%5.68% ✓
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$25.3K$25.6K ✓
Annual income after 10y$459.40$2,637.42 ✓
Total dividends collected$4.1K$13.7K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CAMRF vs NNN ($10,000, DRIP)

YearCAMRF PortfolioCAMRF Income/yrNNN PortfolioNNN Income/yrGap
1$11,064$363.64$10,737$617.02+$327.00 → CAMRF
2$12,214$375.99$11,577$710.93+$637.00 → CAMRF
3$13,457$387.94$12,538$822.59+$919.00 → CAMRF
4$14,798$399.45$13,645$956.06+$1.2K → CAMRF
5$16,245$410.53$14,925$1,116.51+$1.3K → CAMRF
6$17,803$421.18$16,415$1,310.57+$1.4K → CAMRF
7$19,481$431.38$18,158$1,546.77+$1.3K → CAMRF
8$21,286$441.15$20,213$1,836.20+$1.1K → CAMRF
9$23,226$450.49$22,649$2,193.37+$577.00 → CAMRF
10← crossover$25,311$459.40$25,558$2,637.42$247.00 → NNN

CAMRF vs NNN: Complete Analysis 2026

CAMRF — Stock

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Full CAMRF Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this CAMRF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAMRF vs SCHDCAMRF vs JEPICAMRF vs OCAMRF vs KOCAMRF vs MAINCAMRF vs ADCCAMRF vs EPRTCAMRF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.